|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Table 3. Summary of findings compiled using GRADE methodology** | | | | | | | | | | |
| Outcome | No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Effect size  (95% CI) | Certainty | Importance |
| Overall survival | 6 | RCT | Seriousa | Seriousb | Not serious | Not serious | Undetected | OR: 0.75  (0.39−1.44) | ⨁⨁◯◯  Low | Critical |
| Tumor recurrence | 5 | RCT | Seriousa | Not serious | Not serious | Not serious | Undetected | OR: 0.69  (0.40−1.18) | ⨁⨁⨁◯Moderate | Critical |
| Albumin level at 6 mon | 5 | RCT | Seriousa | Not serious | Not serious | Not serious | Undetected | MD: 0.11  (0.02−0.20) | ⨁⨁⨁◯Moderate | Important |
| Cholinesterase level at 12 mon | 1 | RCT | Seriousa | Not serious | Not serious | Seriousc | Undetected | MD: 50.00  (21.08−78.92) | ⨁⨁◯◯Low | Not important |
| Ascites at 12 mon | 4 | RCT | Seriousa | Not serious | Not serious | Not serious | Undetected | RR: 0.39  (0.21−0.71) | ⨁⨁⨁◯Moderate | Important |
| Abbreviations: CI, confidence interval; GRADE, quality of evidence grade; MD, mean difference; OR, odds ratio; RCT, randomized controlled trial; RR, risk ratio;  ⨁⨁⨁◯ moderate certainty; ⨁⨁◯◯ low certainty.  aData reported as downgraded because of the some concern of bias; bData reported as downgraded because of high heterogeneity among the trials; cData reported as downgraded because of wide CI or insufficient studies. | | | | | | | | | | |